{"created":"2023-05-15T14:53:25.681248+00:00","id":72757,"links":{},"metadata":{"_buckets":{"deposit":"890313b3-9c51-47a1-9f37-93b89b4e9028"},"_deposit":{"created_by":1,"id":"72757","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"72757"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00072757","sets":["10:28"]},"author_link":["716609","716611","716610","716612"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2018-04-22","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background / Aims: Gastric cancer (GC) is one of the main causes of cancer-related death. Almost 1/3 of GC patients has distant\nmetastasis at the time of diagnosis. Liver metastasis (LM) is one of the common metastatic pattern of GC, which is classified as\nSTAGE 4. Unfortunately, the therapeutic efficacy of current standard treatments for LMGC are still limited and the five years\nsurvival is less than 10%. It has been reported that about 70% of LMGC are HER2-positive (HER2+), so HER2 can be an attractive\ntherapeutic target. Alpha-radioimmunotherapy (alpha-RIT) is getting higher attention with the advantage of the combination of cancer\nspecific targeting of antibodies and high cell killing effect of alpha-particle. Astatine-211 (211At) is one of the promising alphaemitter,\nwhich has appropriate half-life (7.2 h) and 100% emit alpha-particle during its decay. The aim of this study is to evaluate the\ntherapeutic efficacy of alpha-RIT against HER2+ LMGC using 211At-labeled anti-HER2 antibody, trastuzumab (211At-trastuzumab).\nMethods: A LMGC mouse model was established by transplanting luciferase-labeled NCl-N87, HER2+ human GC cell, to mice from\nsplenic vein. 211At was labeled to trastuzumab by tin-halogen exchange. Biodistribution study was performed to evaluate the tumor\naccumulation of 211At-trastuzumab. Experimental therapy was performed by injecting 211At-trastuzumab (1 MBq) to LMGC mice\nfrom tail vein. The tumor were monitored by luminescence imaging and body weight and the number of white blood cells were\nmonitored to check the toxicity.\nResults: Tumor accumulation of 211At-trastuzumab were increased along with the time and reached about 12% at 24 h post injection.\n211At-trastuzumab effectively eradicated the LMGC in our mouse model while the tumor in the control group were aggressively\ngrown.\nConclusion: Alpha-RIT using 211At-trastuzumab could be a novel therapeutic option for HER2+ LMGC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"12th Congress of the world federation of nuclear medicine and biology","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"716609","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"716610","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"李 惠子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716611","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716612","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Preclinical study of alpha-radioimmunotherapy against HER2+ liver metastasis of gastric cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Preclinical study of alpha-radioimmunotherapy against HER2+ liver metastasis of gastric cancer"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-04-27"},"publish_date":"2018-04-27","publish_status":"0","recid":"72757","relation_version_is_last":true,"title":["Preclinical study of alpha-radioimmunotherapy against HER2+ liver metastasis of gastric cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:36:24.622969+00:00"}